Table 2.

Clinical and tumor genetic data of patients harboring ALK mutations

SampleAge at diagnosis (mo)INSS stageRelapse (yes or no)Follow-up (mo)StatusInterval diagnosis-relapse (mo)Tumoral cells (%)chr 2p copy number at ALK locusMYCN statusALK amplification statusALK F1174 status as detected by Hiseq (% of mutated allele)ALK R1275 status as detected by Hiseq (% of mutated allele)
NB0211T20LocNo155AliveNA903MN-NAALK-NA/28.647
NB0824T34Yes13DOD3953MN-NAALK-NA22.957/
NB0366T3LocNo98AliveNA803MN-NAALK-NA20.899/
NB0183T354No109AliveNA903MNAALK-NA0.787/
NB0194T404Yes10DOD7>502–3MNAALK-NA4.914/
NB0085T24sNo61AliveNA1003MN-NAALK-NA/61.722
NB0222T3LocNo63AliveNA>502MN-NAALK-NA/49.206
NB0230T434Yes21DOD11>502MNAALK-NA0.562/
NB0789T33LocNo56AliveNA803MN-NAALK-NA22.854/
NB0233T344No49AliveNA>504MNAALK-NA/3.648
NB0012T134Yes7DOD5902MNAALK-NA7.657/
NB0372T10LocNo24AliveNA903MN-NAALK-NA/61.443
NB1244T134No40DODNA902MNAALK-NA13.46/
NB0308T3LocYes92Alive21>503MN-NAALK-NA/14.419
NB0186T104No6DODNA802MNAALK-NA10.534/
NB0231T504Yes27DOD19904MNAALK-NA2.750/
NB1129T314No33AliveNA952MNAALK-NA/3.994
NB0535T4LocYes210Alive5802–3MN-NAALK-NA21.198/
NB0014T44Yes10DOD10903MNAALK-NA0.744/
NB0540T104No235AliveNA703–4MN-NAALK-NA/0.811
NB1057T354No39AliveNA502MNAALK-NA/3.109
NB0284T44LocYes6DOD6903MNAALK-NA0.917/
NB0920T44Yes51Alive14902MN-NAALK-NA38.955/
NB0984T244Yes14DOD11>502MNAALK-NA/45.123
NB1001T12LocNo5AliveNA903MN-NAALK-NA/35.499
NB1418T154Yes6DOD6953MNAALK-A/73.001
NB1253T174No140AliveNA>602MNAALK-NA5.323/

NOTE: For 27 patients, ALK mutations were detected at diagnosis by deep sequencing.

Abbreviations: ALK-A, ALK amplified; ALK-NA, ALK not-amplified; D, diagnosis; DOD, dead of disease; INSS, International Neuroblastoma Staging System; Loc, local tumor (stages 1, 2a, 2b or 3); MNA, MYCN amplification; MN-NA, MYCN non-amplified; NA, Not-applicable; /: not applicable.